Loncar Cancer Immunotherapy ETF (CNCR) News CNCR Home News Ratings Charts Dividends Loncar Cancer Immunotherapy ETF (CNCR): $14.96 0.22 (+1.49%) POWR Rating Get Rating Component Grades Buy & Hold C Peer D Trade Get Rating Add CNCR to Watchlist Sign Up Category: Health & Biotech ETFs Category C Ranked #31 of 42 in category See All 'A' Rated Buy ETFs Filter CNCR News Items All News Types Featured Stories AcquisitionAirlineAutomobilesBarron'sBiotechnologyBuffettBusiness/Consumer ServicesBuybackCommentaryCommoditiesConsumer GoodsCorp. NewsCramerDebt OfferingDefenseDividendDow Jones Industrial AverageDowngradeEarningsEconomic DataEnergyETFsFAANGFederal ReserveFinancialFood & BeverageGuidance DownGuidance UpHealthcareHedge FundHomebuildersInsider BuyingInsider SellingIPOsJob CutsLeisure/Arts/HospitalityM&AMarijuanaMediaMetals & MiningMgmt ChangeNew Coverage (Bearish)New Coverage (Bullish)New Coverage (Neutral)OptionsPE InvestmentProduct NewsPT LoweredPT RaisedPT Set (Bearish)PT Set (Bullish)PT Set (Neutral)Rating Reiterated (Bearish)Rating Reiterated (Bullish)Rating Reiterated (Neutral)Real EstateRestaurantsResumes Coverage (Bearish)Resumes Coverage (Bullish)Resumes Coverage (Neutral)RetailRumorSemiconductorSocial MediaSpin-offStock OfferingStock SplitTechnologyTelecomTransportation LogisticsTrumpUpgradeUtilities Search CNCR News Results Date Symbol Company Title Start End Change POWR Rating Loading, please wait... Load More News Items Most Popular Stories View All • Investors: Are You Ready for November? • 3 Cybersecurity Stocks Defending Against Digital Threats • 3 Oil Stocks With High Upside as Global Demand Rebounds • 3 Tech Stocks Under $10 That Could Deliver Big Gains • 2 Concerns for Investors in October View All Top stories Get Free Updates Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! Subscribe
